NotesFAQContact Us
Search Tips
Peer reviewed Peer reviewed
Direct linkDirect link
ERIC Number: EJ777654
Record Type: Journal
Publication Date: 2007-Sep
Pages: 10
Abstractor: Author
Reference Count: 7
ISSN: ISSN-0890-8567
High-Dose Atomoxetine Treatment of ADHD in Youths with Limited Response to Standard Doses
Kratochvil, Christopher J.; Michelson, David; Newcorn, Jeffrey H.; Weiss, Margaret D.; Busner, Joan; Moore, Rodney J.; Ruff, Dustin D.; Ramsey, Janet; Dickson, Ruth; Turgay, Atilla; Saylor, Keith E.; Luber, Stephen; Vaughan, Brigette; Allen, Albert J.
Journal of the American Academy of Child & Adolescent Psychiatry, v46 n9 p1128 Sep 2007
Objective: To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD). Method: Two randomized, double-blind trials of atomoxetine nonresponders ages 6 to 16 years were conducted comparing continued treatment with same-dose atomoxetine to treatment using greater than standard efficacious doses (study 1: up to 3.0 mg x kg[superscript -1] x day [superscript -1]; study 2: up to 2.4 mg x kg[superscript -1] x day[superscript -1]. Results: The primary outcome measure for both studies was mean ADHD Rating Scale (ADHD RS) total score. For study 1 (N = 122), decreases in ADHD RS total scores were not significantly different between treatment groups (mean change [SD]: continued same dose, -8.9 [11.2]; high dose, -9.8 [13.1]; p = 0.595). Likewise, for study 2 (N =125), treatment groups did not differ (mean change [SD]: continued same dose, -6.2 [12.2]; high dose, -8.9 [10.0], p = 0.110). Tolerability was not significantly different between the continued same-dose and high-dose groups. Conclusions: These studies provide evidence that current dose recommendations are appropriate for most patients,suggesting no systematic advantage to increasing atomoxetine doses beyond current guidelines. In both studies, continued treatment, whether at a higher dose or the previous dose, was associated with improved outcomes in patients who demonstrated incomplete/inadequate response to acute ADD treatment, although without a placebo arm, we cannot rule out the possibility that expectancy played a role in symptom improvement. (Contains 2 figures and 4 tables.)
Lippincott Williams & Wilkins. P.O. Box 1600, Hagerstown, MD 21741. Tel: 800-638-3030; Tel: 301-223-2300; Fax: 301-223-2400; Web site:
Publication Type: Journal Articles; Reports - Research
Education Level: N/A
Audience: N/A
Language: English
Sponsor: N/A
Authoring Institution: N/A
Identifiers - Location: United States